Chattem Gets Investors in a Lather

The consumer products maker will acquire five OTC brands from J&J and Pfizer, prompting Brean Murray to upgrade the stock

Investors snapped up shares of Chattem (CHTT) Oct. 6 after the consumer products maker announced plans to acquire the U.S. rights to five over-the-counter brands from Johnson & Johnson (JNJ) and the consumer health care business of Pfizer (PFE) for $410 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.